Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
Zacks
More News
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
Key PointsPfizer aims to enter the weight loss drug market, and one platform should be the workhorse of this effort...
Nasdaq News: Markets
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.
Zacks
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
Pfizer (PFE) closed the most recent trading day at $26.14, moving +2.11% from the previous trading session.
Zacks
Why Pfizer Stock Popped Today
Key PointsRBC upgraded Pfizer stock today, removing its sell rating on the big pharma giant...
Nasdaq News: Markets
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Key PointsLexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs...
Nasdaq News: Markets
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.
Zacks
Here are Wednesday's biggest analyst calls: Nvidia, Tesla, Cava, Netflix, Chipotle, Pfizer, Nike, SharkNinja & more
Here are the biggest calls on Wall Street on Wednesday...
CNBC: Top News
Viral Influencer: How Bill Gates' Billions Shape US Medical Research
Viral Influencer: How Bill Gates' Billions Shape US Medical Research
Authored by Paul D. Thacker via RealClearInvestigations,
Bill Gates has long been one of the most admired people in the world, especially since he stepped down from his role running Microsoft to devote himself and...
Zero Hedge
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.